



10/035,211.



IN THE CLAIMS:


Please enter the following new claims:

45. A vitamin D₃ derivatives expressed by the following general formula [1] or pharmaceutically permissible solvates thereof,



{wherein, R₀₁ and R₀₂ are each independently a hydrogen atom, a trimethylsilyl group, a triethylsilyl group, a t-butyltrimethylsilyl group, an acetyl group, a methoxymethyl group or a tetrahydro-4H-pyran-2-yl group;

Z is represented by formula (1-5),



(1-5)

(in the above formula (1-5),

R₅₁ expresses -CONR₅₁₁R₅₁₂, -COR₅₁₃ or -C(OH)R₅₁₄R₅₁₅, wherein R₅₁₁ and R₅₁₂ are identical to or different from each other, and they are a hydrogen atom or a C₁-C₄ alkyl group, or both the members together express a nitrogen-containing C₃-C₈ alkyl ring or a morpholino group in cooperation with the nitrogen atom to which they are bonded; and R₅₁₃, R₅₁₄ and R₅₁₅ are identical to or different from each other, and they express a C₁-C₄ alkyl group;

R₅₂ expresses a methyl group, an ethyl group, a trifluoromethyl group or a pentafluoroethyl group.

46. A vitamin D₃ derivative or a pharmaceutically permissible solvate thereof described in Claim 45, wherein, in the above formula (1), R₀₁ and R₀₂ are both hydrogen atoms.

47. A vitamin D₃ derivative or a pharmaceutically permissible solvate thereof described in Claim 45, wherein, in the above formula (1), R₅₁ is -CONR₅₁₁R₅₁₂ or -COR₅₁₃.

48. A vitamin D₃ derivative or a pharmaceutically permissible solvate thereof described in Claim 45, wherein, in the above formula (1), R₅₁ is -CONR₅₁₁R₅₁₂.

49. A vitamin D₃ derivative or a pharmaceutically permissible solvate thereof described in Claim 45, wherein, in the above formula (1), R₅₁ is -COR₅₁₃.

50. A vitamin D₃ derivative or a pharmaceutically permissible solvate thereof described in Claim 45, wherein, in the above formula (1), R₅₁ is -CONR₅₁₁R₅₁₂, and R₅₁₁ and R₅₁₂ are identical to or different from each other, and they are a methyl group or an ethyl group, or

are identical to or different from each other, and they are a methyl group or an ethyl group, or both the members together express an aziridine, pyrrolidine, piperidine or morpholino ring in cooperation with the nitrogen atom to which they are bonded.

51. A vitamin D₃ derivative or a pharmaceutically permissible solvate thereof described in Claim 45, wherein, in the above formula (1), R₅₁ is COR₅₁₃, and R₅₁₃ is a methyl group or an ethyl group.

52. A vitamin D₃ derivative or a pharmaceutically permissible solvate thereof described in Claim 45, wherein, in the above formula (1), R₅₂ is a methyl group.

53. A pharmaceutical composition composed of a vitamin D₃ derivative or pharmaceutically permissible solvate thereof described in Claim 45, and a pharmaceutically permissible carrier.

IN THE ABSTRACT OF DISCLOSURE:

Please delete the present Abstract of the Disclosure and replace it with the following new Abstract of the Disclosure:

Compounds expressed by the following general formula (1),